Schering Corporation

Pharmacopeia Drug Discovery, Inc.

Merck Sharp + Dohme Corp.

Pharmacopeia Inc.

Agios Pharmaceuticals, Inc.

Cephalon, Inc.

Ariad Pharmaceuticals, Inc.

Hoffmann-la Roche Inc.

Abbvie Inc.

Tyco Electronics (shanghai) Co., Ltd.

Littelfuse, Inc.

Servier Pharmaceuticals LLC

Ariad Gene Therapeutics, Inc.

Littelfuse Electronics (shanghai) Co., Ltd.

Pharacopeia Drug Discovery, Inc.

Tao Guo

Andrew William Stamford

Kurt William Saionz

Jared N Cumming

Corey Strickland

Ulrich Iserloh

Yusheng Wu

Suresh D Babu

Zhaoning Zhu

Thuy X H Le

William J Greenlee

Brian Alexander McKittrick

Elizabeth M Smith

Rachael Catherine Hunter

Ying Huang

Douglas Walsh Hobbs

Lingyan Wang

Johannes H Voigt

Zhong-Yue Sun

John P Caldwell

Yuanzan C Ye

Gang Qian

Michelle Lee Morris

Robert D Mazzola, Jr

Fang Liu

Jeremy Mark Travins

Guoqing Li

Yuefei Shao

Francesco Gerald Salituro

Jeffrey O Saunders

Janeta Popovici-Muller

Shunqi Yan

Giovanni Cianchetta

Jianping Pan

Samuel Chackalamannil

Wu Yang

Yan Xia

Dennis Alan Holt

Terence P Keenan

Edgardo Laborde

Roland Ellwood Dolle

Li Chen

John W Clader

Bin Wang

Bruce D Dorsey

Hubert B Josien

Koc-Kan Ho

Hongying Yun

Henry Joseph Breslin

Lisha Wang

Lichun Feng

Gregory R Ott

Rabindranath Tripathy

Theodros Asberom

Edward McDonald

Craig A Zificsak

Yongfu Liu

Chungen Liang

James L Diebold

Xiufang Zheng

Song Feng

Lu Gao

Diane E Gingrich

Keith S Learn

Karen L Milkiewicz

Eugen F Mesaros

Benjamin J Dugan

Zhen Min He

Xihan Wu

Xiaoxiang Liu

Jim Zhen Wu

John J Baldwin

Ravi P Nargund

Robert L Hudkins

Anandan Palani

Edward R Bacon

Duane A Burnett

Peng Li

Lijuan Jane Wang

Dong Xiao

Xueqing Wang

Wen-Lian Wu

Xing Dai

Shuwen He

Allison L Zulli

Hong Liu

Dmitri A Pissarnitski

Ming Tao

Michael D Meyer

Nadine C Becknell

Linda Brockunier

Xuanjia Peng

Reddeppa Reddy Dandu

Robert A Horlick

Thavalakulamgara K Sasikumar

Wei Jun Zheng

Guizhen Dong

Nicolas Zorn

Chia-Yu Huang

A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein Rto R, A, Q, X and Y are as defined in the specification and claims, and their use as a pharmaceutical for the treatment or prophylaxis of respiratory syncytial virus disease.

Compounds for the treatment and prophylaxis of respiratory syncytial virus disease

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

Therapeutically active compounds and their methods of use

A circuit protection device including a PTC device and a diode. A first insulation layer is formed between first electrode surfaces of the diode and the PTC device. Vias for thermally and electrically connecting the first electrode surfaces of the diode and the PTC device are formed in the first insulation layer. First, second, and third external electrode pads are provided on a second insulation layer formed on the second electrode surface of the PTC device. The second electrode surface of the PTC device is electrically connected to the first external electrode pad. The first electrode surface of the diode and the first electrode surface of the PTC device are electrically connected to the second external electrode pad. A second electrode surface of the diode is electrically connected to the third external electrode pad.

Circuit protection device

A cable is provided and includes a first conductor, a second conductor, and a PTC material layer. The PTC material layer is directly bonded to and electrically connects the first conductor and the second conductor.

Cable and method of manufacturing the same

Therapeutically active compositions and their methods of use

A circuit protection device is provided and includes a first insulation layer, a second insulation layer, a thermal fuse, a diode, a first exterior electrode pad, a second exterior electrode pad, and a third exterior electrode pad. The second insulation layer is positioned above a top surface of the first insulation layer. The thermal fuse is packaged in the first insulation layer and having a first electrode end and a second electrode end positioned opposite to the first electrode end. The diode is packaged in the second insulation layer and having a first electrode surface and a second electrode surface positioned opposite to the first electrode surface. The first exterior electrode pad is positioned on a bottom surface of the first insulation layer and electrically connected to the first electrode surface and the first electrode end. The second exterior electrode pad is positioned on the bottom surface and electrically connected to the second electrode end, while the third exterior electrode pad is positioned on the bottom surface and electrically connected to the second electrode surface.

The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. 

Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C

Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein  and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a &#x3b2;-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

Cyclic amide BACE-1 inhibitors having a benzamide substituent

Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W, X, U, R, R, R, and R, are as defined herein, and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic antagonist.

Heterocyclic aspartyl protease inhibitors

Disclosed herein are chemokine receptor antagonists of formula (I) wherein R, R, and Rare as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

Chemokine receptor antagonists

Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease

Growing community of inventors

Dayton, NJ, United States of America

Tao Guo